- Home
- PMCB vs CHRO Comparison
PMCB vs CHRO Comparison
Compare PMCB & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- CHRO
- Stock Information
- Founded
- PMCB 1996
- CHRO 2002
- Country
- PMCB United States
- CHRO United States
- Employees
- PMCB N/A
- CHRO N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- CHRO
- Sector
- PMCB Health Care
- CHRO
- Exchange
- PMCB Nasdaq
- CHRO Nasdaq
- Market Cap
- PMCB 7.6M
- CHRO 7.6M
- IPO Year
- PMCB N/A
- CHRO 2024
- Fundamental
- Price
- PMCB $1.05
- CHRO $1.35
- Analyst Decision
- PMCB
- CHRO
- Analyst Count
- PMCB 0
- CHRO 0
- Target Price
- PMCB N/A
- CHRO N/A
- AVG Volume (30 Days)
- PMCB 8.5K
- CHRO 135.3K
- Earning Date
- PMCB 08-12-2025
- CHRO 08-12-2025
- Dividend Yield
- PMCB N/A
- CHRO N/A
- EPS Growth
- PMCB N/A
- CHRO N/A
- EPS
- PMCB 1.29
- CHRO N/A
- Revenue
- PMCB N/A
- CHRO N/A
- Revenue This Year
- PMCB N/A
- CHRO N/A
- Revenue Next Year
- PMCB N/A
- CHRO N/A
- P/E Ratio
- PMCB $0.82
- CHRO N/A
- Revenue Growth
- PMCB N/A
- CHRO N/A
- 52 Week Low
- PMCB $1.00
- CHRO $0.45
- 52 Week High
- PMCB $2.42
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- PMCB 47.26
- CHRO 63.60
- Support Level
- PMCB $1.00
- CHRO $1.12
- Resistance Level
- PMCB $1.07
- CHRO $1.23
- Average True Range (ATR)
- PMCB 0.05
- CHRO 0.16
- MACD
- PMCB 0.01
- CHRO 0.01
- Stochastic Oscillator
- PMCB 39.78
- CHRO 30.26
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.